{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:31:28Z","timestamp":1793766688247,"version":"4.6.1"},"reference-count":149,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["IK2CX001495"],"award-info":[{"award-number":["IK2CX001495"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00213-022-06083-y","type":"journal-article","created":{"date-parts":[[2022,3,6]],"date-time":"2022-03-06T22:02:45Z","timestamp":1646604165000},"page":"1945-1976","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review"],"prefix":"10.1007","volume":"239","author":[{"given":"Aryan","family":"Sarparast","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelan","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Malcolm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Stauffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,7]]},"reference":[{"issue":"8","key":"6083_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1093\/jat\/33.8.439","volume":"33","author":"TT Abraham","year":"2009","unstructured":"Abraham TT, Barnes AJ, Lowe RH, Spargo EAK, Milman G, Pirnay SO, Gorelick DA, Goodwin RS, Huestis MA (2009) Urinary MDMA, MDA, HMMA, and HMA Excretion Following Controlled MDMA Administration to Humans. J Anal Toxicol 33(8):439\u2013446","journal-title":"J Anal Toxicol"},{"issue":"5","key":"6083_CR2","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/j.1472-8206.2005.00355.x","volume":"19","author":"S Akhondzadeh","year":"2005","unstructured":"Akhondzadeh S, Hampa AD (2005) Topiramate prevents ecstasy consumption: A case report. Fundam Clin Pharmacol 19(5):601\u2013602. https:\/\/doi.org\/10.1111\/j.1472-8206.2005.00355.x","journal-title":"Fundam Clin Pharmacol"},{"issue":"6","key":"6083_CR3","doi-asserted-by":"publisher","first-page":"201","DOI":"10.5498\/wjp.v11.i6.201","volume":"11","author":"H Artin","year":"2021","unstructured":"Artin H, Zisook S, Ramanathan D (2021) How do serotonergic psychedelics treat depression: The potential role of neuroplasticity. World J Psychiatr 11(6):201\u2013214. https:\/\/doi.org\/10.5498\/wjp.v11.i6.201","journal-title":"World J Psychiatr"},{"issue":"6","key":"6083_CR4","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1177\/0269881115581962","volume":"29","author":"MJ Baggott","year":"2015","unstructured":"Baggott MJ, Kirkpatrick MG, Bedi G, de Wit H (2015) Intimate insight: MDMA changes how people talk about significant others. J Psychopharmacol 29(6):669\u2013677. https:\/\/doi.org\/10.1177\/0269881115581962","journal-title":"J Psychopharmacol"},{"issue":"12","key":"6083_CR5","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1177\/0269881116678781","volume":"30","author":"FS Barrett","year":"2016","unstructured":"Barrett FS, Bradstreet MP, Leoutsakos JMS, Johnson MW, Griffiths RR (2016) The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms. J Psychopharmacol 30(12):1279\u20131295","journal-title":"J Psychopharmacol"},{"key":"6083_CR6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/7854_2017_474","volume":"36","author":"FS Barrett","year":"2018","unstructured":"Barrett FS, Griffiths RR (2018) Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates. Curr Top Behav Neurosci 36:393\u2013430. https:\/\/doi.org\/10.1007\/7854_2017_474","journal-title":"Curr Top Behav Neurosci"},{"issue":"1\u20132","key":"6083_CR7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0014-2999(88)90056-8","volume":"149","author":"G Battaglia","year":"1988","unstructured":"Battaglia G, Brooks BP, Kulsakdinun C, De Souza EB (1988) Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol 149(1\u20132):159\u2013163. https:\/\/doi.org\/10.1016\/0014-2999(88)90056-8","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"6083_CR8","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/j.1360-0443.2006.01423.x","volume":"101","author":"CA Baylen","year":"2006","unstructured":"Baylen CA, Rosenberg H (2006) A review of the acute subjective effects of MDMA\/ecstasy. Addiction 101(7):933\u2013947. https:\/\/doi.org\/10.1111\/j.1360-0443.2006.01423.x","journal-title":"Addiction"},{"key":"6083_CR9","doi-asserted-by":"publisher","unstructured":"Becker AM, Holze F, Grandinetti T, Klaiber A, Toedtli VE, Kolaczynska KE, Duthaler U, Varghese N, Eckert A, Gr\u00fcnblatt E, Liechti ME (2021) Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects. Clin Pharmacol Ther n\/a(n\/a). https:\/\/doi.org\/10.1002\/cpt.2487","DOI":"10.1002\/cpt.2487"},{"issue":"2","key":"6083_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1046\/j.0306-5251.2001.01548.x","volume":"53","author":"L Bertilsson","year":"2002","unstructured":"Bertilsson L, Dahl M-L, Dal\u00e9n P, Al-Shurbaji A (2002) Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs: Molecular genetics of CYP2D6. Br J Clin Pharmacol 53(2):111\u2013122. https:\/\/doi.org\/10.1046\/j.0306-5251.2001.01548.x","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"6083_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0145635","volume":"10","author":"MB Bigler","year":"2015","unstructured":"Bigler MB, Egli SB, Hysek CM, Hoenger G, Schmied L, Baldin FS, Marquardsen FA, Recher M, Liechti ME, Hess C, Berger CT (2015) Stress-Induced In Vivo Recruitment of Human Cytotoxic Natural Killer Cells Favors Subsets with Distinct Receptor Profiles and Associates with Increased Epinephrine Levels. PLoS ONE 10(12):e0145635. https:\/\/doi.org\/10.1371\/journal.pone.0145635","journal-title":"PLoS ONE"},{"issue":"10","key":"6083_CR12","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1093\/ndt\/13.10.2654","volume":"13","author":"C Bingham","year":"1998","unstructured":"Bingham C (1998) Necrotizing renal vasculopathy resulting in chronic renal failure after ingestion of methamphetamine and 3,4-methylenedioxymethamphetamine ('ecstasy\u2019). Nephrol Dial Transplant 13(10):2654\u20132655. https:\/\/doi.org\/10.1093\/ndt\/13.10.2654","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"6083_CR13","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1176\/appi.ajp.2009.09020186","volume":"167","author":"P Blier","year":"2010","unstructured":"Blier P, Ward HE, Tremblay P, Laberge L, H\u00e9bert C, Bergeron R (2010) Combination of Antidepressant Medications From Treatment Initiation for Major Depressive Disorder: A Double-Blind Randomized Study. Am J Psychiatry 167(3):281\u2013288. https:\/\/doi.org\/10.1176\/appi.ajp.2009.09020186","journal-title":"Am J Psychiatry"},{"issue":"4\u20135","key":"6083_CR14","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0197-0186(03)00027-5","volume":"43","author":"IL Bogen","year":"2003","unstructured":"Bogen IL, Haug KH, Myhre O, Fonnum F (2003) Short- and long-term effects of MDMA (\u201cecstasy\u201d) on synaptosomal and vesicular uptake of neurotransmitters in vitro and ex vivo. Neurochem Int 43(4\u20135):393\u2013400. https:\/\/doi.org\/10.1016\/S0197-0186(03)00027-5","journal-title":"Neurochem Int"},{"issue":"3","key":"6083_CR15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/0269881114565144","volume":"29","author":"MP Bogenschutz","year":"2015","unstructured":"Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa P, Strassman RJ (2015) Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J Psychopharmacol 29(3):289\u2013299. https:\/\/doi.org\/10.1177\/0269881114565144","journal-title":"J Psychopharmacol"},{"issue":"4\u20135","key":"6083_CR16","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S0028-3908(97)00049-X","volume":"36","author":"DW Bonhaus","year":"1997","unstructured":"Bonhaus DW, Weinhardt KK, Taylor M, Desouza A, Mcneeley PM, Szczepanski K, Fontana DJ, Trinh J, Rocha CL, Dawson MW, Flippin LA, Eglen RM (1997) RS-102221: A Novel High Affinity and Selective, 5-HT 2C Receptor Antagonist. Neuropharmacology 36(4\u20135):621\u2013629. https:\/\/doi.org\/10.1016\/S0028-3908(97)00049-X","journal-title":"Neuropharmacology"},{"issue":"6","key":"6083_CR17","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/0893-133X(95)00145-4","volume":"14","author":"K Bonson","year":"1996","unstructured":"Bonson K (1996) Chronic Administration of Serotonergic Antidepressants Attenuates the Subjective Effects of LSD in Humans. Neuropsychopharmacology 14(6):425\u2013436. https:\/\/doi.org\/10.1016\/0893-133X(95)00145-4","journal-title":"Neuropsychopharmacology"},{"issue":"1\u20132","key":"6083_CR18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3109\/15563659809162584","volume":"36","author":"KS Borowiak","year":"1998","unstructured":"Borowiak KS, Ciechanowski K, Waloszczyk P (1998) Psilocybin mushroom (Psilocybe semilanceata) intoxication with myocardial infarction. J Toxicol Clin Toxicol 36(1\u20132):47\u201349. https:\/\/doi.org\/10.3109\/15563659809162584","journal-title":"J Toxicol Clin Toxicol"},{"issue":"12","key":"6083_CR19","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s40262-017-0540-6","volume":"56","author":"RT Brown","year":"2017","unstructured":"Brown RT, Nicholas CR, Cozzi NV, Gassman MC, Cooper KM, Muller D, Thomas CD, Hetzel SJ, Henriquez KM, Ribaudo AS, Hutson PR (2017) Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults. Clin Pharmacokinet 56(12):1543\u20131554. https:\/\/doi.org\/10.1007\/s40262-017-0540-6","journal-title":"Clin Pharmacokinet"},{"issue":"15","key":"6083_CR20","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ (2021) Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med 384(15):1402\u20131411. https:\/\/doi.org\/10.1056\/NEJMoa2032994","journal-title":"N Engl J Med"},{"key":"6083_CR21","doi-asserted-by":"publisher","unstructured":"Carhart-Harris R, Leech R, Hellyer PJ, Shanahan M, Feilding A, Tagliazucchi E, Chialvo DR, Nutt D (2014) The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci 8. https:\/\/doi.org\/10.3389\/fnhum.2014.00020","DOI":"10.3389\/fnhum.2014.00020"},{"issue":"9","key":"6083_CR22","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1177\/0269881117725915","volume":"31","author":"R Carhart-Harris","year":"2017","unstructured":"Carhart-Harris R, Nutt D (2017) Serotonin and brain function: A tale of two receptors. J Psychopharmacol 31(9):1091\u20131120. https:\/\/doi.org\/10.1177\/0269881117725915","journal-title":"J Psychopharmacol"},{"issue":"2","key":"6083_CR23","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0006-3223(01)01262-8","volume":"51","author":"LL Carpenter","year":"2002","unstructured":"Carpenter LL, Yasmin S, Price LH (2002) A double-blind, placebo-controlled study of antidepressant augementation with mirtazapine. Biol Psychiat 51(2):183\u2013188. https:\/\/doi.org\/10.1016\/S0006-3223(01)01262-8","journal-title":"Biol Psychiat"},{"key":"6083_CR24","doi-asserted-by":"publisher","unstructured":"Castro Santos H, Gama Marques J (2021) What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A Systematic Review Porto Biomedical Journal 6(1):e128. https:\/\/doi.org\/10.1097\/j.pbj.0000000000000128","DOI":"10.1097\/j.pbj.0000000000000128"},{"key":"6083_CR25","unstructured":"Center for Behavioral Health Statistics and Quality (2020) National Survey on Drug Use and Health\u20142019. Substance Abuse and Mental Health Services Administration. https:\/\/www.samhsa.gov\/data\/"},{"issue":"5","key":"6083_CR26","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.apsb.2016.04.005","volume":"6","author":"S Cho","year":"2016","unstructured":"Cho S, Ning M, Zhang Y, Rubin LH, Jeong H (2016) 17\u03b2-Estradiol up-regulates UDP-glucuronosyltransferase 1A9 expression via estrogen receptor \u03b1. Acta Pharmaceutica Sinica B 6(5):504\u2013509. https:\/\/doi.org\/10.1016\/j.apsb.2016.04.005","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"1","key":"6083_CR27","doi-asserted-by":"publisher","first-page":"5997","DOI":"10.1038\/s41598-021-85389-x","volume":"11","author":"IV Cohen","year":"2021","unstructured":"Cohen IV, Makunts T, Abagyan R, Thomas K (2021) Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database. Sci Rep 11(1):5997. https:\/\/doi.org\/10.1038\/s41598-021-85389-x","journal-title":"Sci Rep"},{"issue":"7599","key":"6083_CR28","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/nature17629","volume":"532","author":"JA Coleman","year":"2016","unstructured":"Coleman JA, Green EM, Gouaux E (2016) X-ray structures and mechanism of the human serotonin transporter. Nature 532(7599):334\u2013339. https:\/\/doi.org\/10.1038\/nature17629","journal-title":"Nature"},{"issue":"2","key":"6083_CR29","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.addbeh.2005.05.025","volume":"31","author":"J Copeland","year":"2006","unstructured":"Copeland J, Dillon P, Gascoigne M (2006) Ecstasy and the concomitant use of pharmaceuticals. Addict Behav 31(2):367\u2013370. https:\/\/doi.org\/10.1016\/j.addbeh.2005.05.025","journal-title":"Addict Behav"},{"issue":"11","key":"6083_CR30","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1007\/s00213-018-5010-9","volume":"235","author":"AL Danforth","year":"2018","unstructured":"Danforth AL, Grob CS, Struble C, Feduccia AA, Walker N, Jerome L, Yazar-Klosinski B, Emerson A (2018) Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: A randomized, double-blind, placebo-controlled pilot study. Psychopharmacology 235(11):3137\u20133148. https:\/\/doi.org\/10.1007\/s00213-018-5010-9","journal-title":"Psychopharmacology"},{"issue":"5","key":"6083_CR31","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2021","unstructured":"Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, Finan PH, Griffiths RR (2021) Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiat 78(5):481\u2013489. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.3285","journal-title":"JAMA Psychiat"},{"issue":"1","key":"6083_CR32","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/JCP.0b013e3181c827ae","volume":"30","author":"J De Jong","year":"2010","unstructured":"De Jong J, Wauben P, Huijbrechts I, Oolders H, Haffmans J (2010) Doxazosin treatment for posttraumatic stress disorder. J Clin Psychopharmacol 30(1):84\u201385. https:\/\/doi.org\/10.1097\/JCP.0b013e3181c827ae","journal-title":"J Clin Psychopharmacol"},{"key":"6083_CR33","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.neuropharm.2014.03.008","volume":"87","author":"DSF Perna","year":"2014","unstructured":"Perna DSF, E. B., Theunissen, E. L., Kuypers, K. P., Heckman, P., de la Torre, R., Farre, M., & Ramaekers, J. G. (2014) Memory and mood during MDMA intoxication, with and without memantine pretreatment. Neuropharmacology 87:198\u2013205. https:\/\/doi.org\/10.1016\/j.neuropharm.2014.03.008","journal-title":"Neuropharmacology"},{"issue":"2","key":"6083_CR34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jemermed.2003.05.007","volume":"26","author":"JH Delgado","year":"2004","unstructured":"Delgado JH, Caruso MJ, Waksman JC, Honigman B, Stillman D (2004) Acute, transient urinary retention from combined ecstasy and methamphetamine use. J Emerg Med 26(2):173\u2013175. https:\/\/doi.org\/10.1016\/j.jemermed.2003.05.007","journal-title":"J Emerg Med"},{"issue":"1","key":"6083_CR35","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1080\/03602532.2016.1278228","volume":"49","author":"RJ Dinis-Oliveira","year":"2017","unstructured":"Dinis-Oliveira RJ (2017) Metabolism of psilocybin and psilocin: Clinical and forensic toxicological relevance. Drug Metab Rev 49(1):84\u201391. https:\/\/doi.org\/10.1080\/03602532.2016.1278228","journal-title":"Drug Metab Rev"},{"issue":"3","key":"6083_CR36","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1515\/ijamh-2013-0052","volume":"25","author":"Y Dobry","year":"2013","unstructured":"Dobry Y, Rice T, Sher L (2013) Ecstasy use and serotonin syndrome: A neglected danger to adolescents and young adults prescribed selective serotonin reuptake inhibitors. Int J Adolesc Med Health 25(3):193\u2013199. https:\/\/doi.org\/10.1515\/ijamh-2013-0052","journal-title":"Int J Adolesc Med Health"},{"issue":"2","key":"6083_CR37","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/02791072.2019.1587556","volume":"51","author":"J Dore","year":"2019","unstructured":"Dore J, Turnipseed B, Dwyer S, Turnipseed A, Andries J, Ascani G, Monnette C, Huidekoper A, Strauss N, Wolfson P (2019) Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy. J Psychoactive Drugs 51(2):189\u2013198. https:\/\/doi.org\/10.1080\/02791072.2019.1587556","journal-title":"J Psychoactive Drugs"},{"issue":"4","key":"6083_CR38","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/s11920-012-0284-9","volume":"14","author":"BA English","year":"2012","unstructured":"English BA, Dortch M, Ereshefsky L, Jhee S (2012) Clinically Significant Psychotropic Drug-Drug Interactions in the Primary Care Setting. Curr Psychiatry Rep 14(4):376\u2013390. https:\/\/doi.org\/10.1007\/s11920-012-0284-9","journal-title":"Curr Psychiatry Rep"},{"issue":"3\u20134","key":"6083_CR39","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s00213-004-1789-7","volume":"173","author":"M Farr\u00e9","year":"2004","unstructured":"Farr\u00e9 M, de la Torre R, Math\u00fana BO, Roset PN, Peir\u00f3 AM, Torrens M, Ortu\u00f1o J, Pujadas M, Cam\u00ed J (2004) Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology (Berl) 173(3\u20134):364\u201375","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"6083_CR40","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1124\/jpet.107.129056","volume":"323","author":"M Farr\u00e9","year":"2007","unstructured":"Farr\u00e9 M, Abanades S, Roset PN, Peir\u00f3 AM, Torrens M, O\u2019Math\u00fana B, Segura M, de la Torre R (2007) Pharmacological Interaction between 3,4-Methylenedioxymethamphetamine (Ecstasy) and Paroxetine: Pharmacological Effects and Pharmacokinetics. J Pharmacol Exp Ther 323(3):954\u2013962. https:\/\/doi.org\/10.1124\/jpet.107.129056","journal-title":"J Pharmacol Exp Ther"},{"key":"6083_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-020-05710-w","author":"AA Feduccia","year":"2020","unstructured":"Feduccia AA, Jerome L, Mithoefer MC, Holland J (2020) Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy. Psychopharmacology. https:\/\/doi.org\/10.1007\/s00213-020-05710-w","journal-title":"Psychopharmacology"},{"key":"6083_CR42","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.pnpbp.2018.03.003","volume":"84","author":"AA Feduccia","year":"2018","unstructured":"Feduccia AA, Mithoefer MC (2018) MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms? Prog Neuropsychopharmacol Biol Psychiatry 84:221\u2013228. https:\/\/doi.org\/10.1016\/j.pnpbp.2018.03.003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"6083_CR43","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ejphar.2003.08.077","volume":"479","author":"AE Fleckenstein","year":"2003","unstructured":"Fleckenstein AE, Hanson GR (2003) Impact of psychostimulants on vesicular monoamine transporter function. Eur J Pharmacol 479(1):283\u2013289. https:\/\/doi.org\/10.1016\/j.ejphar.2003.08.077","journal-title":"Eur J Pharmacol"},{"key":"6083_CR44","doi-asserted-by":"publisher","DOI":"10.1037\/pha0000490","author":"C Fogg","year":"2021","unstructured":"Fogg C, Michaels TI, de la Salle S, Jahn ZW, Williams MT (2021) Ethnoracial health disparities and the ethnopsychopharmacology of psychedelic-assisted psychotherapies. Exp Clin Psychopharmacol. https:\/\/doi.org\/10.1037\/pha0000490","journal-title":"Exp Clin Psychopharmacol"},{"issue":"6","key":"6083_CR45","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/j.1360-0443.2004.00744.x","volume":"99","author":"RS Gable","year":"2004","unstructured":"Gable RS (2004) Comparison of acute lethal toxicity of commonly abused psychoactive substances. Addiction 99(6):686\u2013696. https:\/\/doi.org\/10.1111\/j.1360-0443.2004.00744.x","journal-title":"Addiction"},{"issue":"2","key":"6083_CR46","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/jts.22479","volume":"33","author":"I Gorman","year":"2020","unstructured":"Gorman I, Belser AB, Jerome L, Hennigan C, Shechet B, Hamilton S, Yazar-Klosinski B, Emerson A, Feduccia AA (2020) Posttraumatic Growth After MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder. J Trauma Stress 33(2):161\u2013170. https:\/\/doi.org\/10.1002\/jts.22479","journal-title":"J Trauma Stress"},{"issue":"6","key":"6083_CR47","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1177\/0269881108094300","volume":"22","author":"RR Griffiths","year":"2008","unstructured":"Griffiths RR, Richards WA, Johnson MW, McCann UD, Jesse R (2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. Journal of Psychopharmacology (oxford, England) 22(6):621\u2013632. https:\/\/doi.org\/10.1177\/0269881108094300","journal-title":"Journal of Psychopharmacology (oxford, England)"},{"key":"6083_CR48","doi-asserted-by":"publisher","unstructured":"Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187(3), 268\u2013283 284\u2013292. https:\/\/doi.org\/10.1007\/s00213-006-0457-5","DOI":"10.1007\/s00213-006-0457-5"},{"key":"6083_CR49","unstructured":"Grob, C. S., & Grigsby, J. (Eds.). (2021). Handbook of medical hallucinogens. The Guilford Press."},{"issue":"1","key":"6083_CR50","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/0166-4328(96)00078-2","volume":"73","author":"CS Grob","year":"1995","unstructured":"Grob CS, Poland RE, Chang L, Ernst T (1995) Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: Methodological considerations and preliminary observations. Behav Brain Res 73(1):103\u2013107. https:\/\/doi.org\/10.1016\/0166-4328(96)00078-2","journal-title":"Behav Brain Res"},{"issue":"5","key":"6083_CR51","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S2215-0366(17)30015-9","volume":"4","author":"CJ Harmer","year":"2017","unstructured":"Harmer CJ, Duman RS, Cowen PJ (2017) How do antidepressants work? New perspectives for refining future treatment approaches. The Lancet Psychiatry 4(5):409\u2013418. https:\/\/doi.org\/10.1016\/S2215-0366(17)30015-9","journal-title":"The Lancet Psychiatry"},{"issue":"2","key":"6083_CR52","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","volume":"172","author":"F Hasler","year":"2004","unstructured":"Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX (2004) Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology (Berl) 172(2):145\u201356","journal-title":"Psychopharmacology (Berl)"},{"issue":"8","key":"6083_CR53","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1177\/0269881108094650","volume":"23","author":"F Hasler","year":"2009","unstructured":"Hasler F, Studerus E, Lindner K, Ludewig S, Vollenweider F (2009) Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA. J Psychopharmacol 23(8):923\u2013935. https:\/\/doi.org\/10.1177\/0269881108094650","journal-title":"J Psychopharmacol"},{"issue":"6","key":"6083_CR54","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.neuropharm.2005.08.008","volume":"49","author":"B Hilber","year":"2005","unstructured":"Hilber B, Scholze P, Dorostkar MM, Sandtner W, Holy M, Boehm S, Singer EA, Sitte HH (2005) Serotonin-transporter mediated efflux: A pharmacological analysis of amphetamines and non-amphetamines. Neuropharmacology 49(6):811\u2013819. https:\/\/doi.org\/10.1016\/j.neuropharm.2005.08.008","journal-title":"Neuropharmacology"},{"issue":"11","key":"6083_CR55","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/BF02160424","volume":"14","author":"A Hofmann","year":"1958","unstructured":"Hofmann A, Frey A, Ott H, Petrzilka Th, Troxler F (1958) Konstitutionsaufkl\u00e4rung und Synthese von Psilocybin. Experientia 14(11):397\u2013399. https:\/\/doi.org\/10.1007\/BF02160424","journal-title":"Experientia"},{"issue":"2","key":"6083_CR56","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1124\/jpet.111.188425","volume":"340","author":"CM Hysek","year":"2012","unstructured":"Hysek CM, Brugger R, Simmler LD, Bruggisser M, Donzelli M, Grouzmann E, Hoener MC, Liechti ME (2012a) Effects of the \u03b1 2 -Adrenergic Agonist Clonidine on the Pharmacodynamics and Pharmacokinetics of 3,4-Methylenedioxymethamphetamine in Healthy Volunteers. J Pharmacol Exp Ther 340(2):286\u2013294. https:\/\/doi.org\/10.1124\/jpet.111.188425","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"6083_CR57","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s00213-012-2645-9","volume":"222","author":"CM Hysek","year":"2012","unstructured":"Hysek CM, Domes G, Liechti ME (2012b) MDMA enhances \u201cmind reading\u201d of positive emotions and impairs \u201cmind reading\u201d of negative emotions. Psychopharmacology 222(2):293\u2013302. https:\/\/doi.org\/10.1007\/s00213-012-2645-9","journal-title":"Psychopharmacology"},{"issue":"5","key":"6083_CR58","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1097\/JCP.0b013e3182979d32","volume":"33","author":"CM Hysek","year":"2013","unstructured":"Hysek CM, Fink AE, Simmler LD, Donzelli M, Grouzmann E, Liechti ME (2013) \u03911-Adrenergic receptors contribute to the acute effects of 3,4-methylenedioxymethamphetamine in humans. J Clin Psychopharmacol 33(5):658\u2013666. https:\/\/doi.org\/10.1097\/JCP.0b013e3182979d32","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"6083_CR59","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00213-012-2761-6","volume":"224","author":"CM Hysek","year":"2012","unstructured":"Hysek CM, Liechti ME (2012) Effects of MDMA alone and after pretreatment with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin on pupillary light reflex. Psychopharmacology 224(3):363\u2013376. https:\/\/doi.org\/10.1007\/s00213-012-2761-6","journal-title":"Psychopharmacology"},{"issue":"8","key":"6083_CR60","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1111\/j.1476-5381.2012.01936.x","volume":"166","author":"CM Hysek","year":"2012","unstructured":"Hysek CM, Schmid Y, Rickli A, Simmler L, Donzelli M, Grouzmann E, Liechti ME (2012c) Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans. Br J Pharmacol 166(8):2277\u20132288. https:\/\/doi.org\/10.1111\/j.1476-5381.2012.01936.x","journal-title":"Br J Pharmacol"},{"issue":"11","key":"6083_CR61","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1093\/scan\/nst161","volume":"9","author":"CM Hysek","year":"2014","unstructured":"Hysek CM, Schmid Y, Simmler LD, Domes G, Heinrichs M, Eisenegger C, Preller KH, Quednow BB, Liechti ME (2014a) MDMA enhances emotional empathy and prosocial behavior. Social Cognitive and Affective Neuroscience 9(11):1645\u20131652. https:\/\/doi.org\/10.1093\/scan\/nst161","journal-title":"Social Cognitive and Affective Neuroscience"},{"issue":"2","key":"6083_CR62","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/clpt.2011.78","volume":"90","author":"CM Hysek","year":"2011","unstructured":"Hysek CM, Simmler LD, Ineichen M, Grouzmann E, Hoener MC, Brenneisen R, Huwyler J, Liechti ME (2011) The Norepinephrine Transporter Inhibitor Reboxetine Reduces Stimulant Effects of MDMA (\u201cEcstasy\u201d) in Humans. Clin Pharmacol Ther 90(2):246\u2013255. https:\/\/doi.org\/10.1038\/clpt.2011.78","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"6083_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036476","volume":"7","author":"CM Hysek","year":"2012","unstructured":"Hysek CM, Simmler LD, Nicola VG, Vischer N, Donzelli M, Kr\u00e4henb\u00fchl S, Grouzmann E, Huwyler J, Hoener MC, Liechti ME (2012d) Duloxetine Inhibits Effects of MDMA (\u201cEcstasy\") In Vitro and in Humans in a Randomized Placebo-Controlled Laboratory Study. PLoS ONE 7(5):e36476. https:\/\/doi.org\/10.1371\/journal.pone.0036476","journal-title":"PLoS ONE"},{"issue":"03","key":"6083_CR64","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1017\/S1461145713001132","volume":"17","author":"CM Hysek","year":"2014","unstructured":"Hysek CM, Simmler LD, Schillinger N, Meyer N, Schmid Y, Donzelli M, Grouzmann E, Liechti ME (2014b) Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination. Int J Neuropsychopharmacol 17(03):371\u2013381. https:\/\/doi.org\/10.1017\/S1461145713001132","journal-title":"Int J Neuropsychopharmacol"},{"issue":"8","key":"6083_CR65","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1136\/emj.2009.079905","volume":"27","author":"CM Hysek","year":"2010","unstructured":"Hysek CM, Vollenweider FX, Liechti ME (2010) Effects of a beta-blocker on the cardiovascular response to MDMA (Ecstasy). Emergency Medicine Journal\u202f: EMJ 27(8):586\u2013589. https:\/\/doi.org\/10.1136\/emj.2009.079905","journal-title":"Emergency Medicine Journal : EMJ"},{"issue":"8","key":"6083_CR66","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1007\/s00213-020-05548-2","volume":"237","author":"L Jerome","year":"2020","unstructured":"Jerome L, Feduccia AA, Wang JB, Hamilton S, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R (2020) Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: A longitudinal pooled analysis of six phase 2 trials. Psychopharmacology 237(8):2485\u20132497. https:\/\/doi.org\/10.1007\/s00213-020-05548-2","journal-title":"Psychopharmacology"},{"issue":"11","key":"6083_CR67","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","volume":"28","author":"MW Johnson","year":"2014","unstructured":"Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR (2014) Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol 28(11):983\u2013992. https:\/\/doi.org\/10.1177\/0269881114548296","journal-title":"J Psychopharmacol"},{"key":"6083_CR68","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","volume":"142","author":"MW Johnson","year":"2018","unstructured":"Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE (2018) The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology 142:143\u2013166. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.05.012","journal-title":"Neuropharmacology"},{"key":"6083_CR69","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pharmthera.2018.11.010","volume":"197","author":"MW Johnson","year":"2019","unstructured":"Johnson MW, Hendricks PS, Barrett FS, Griffiths RR (2019) Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol Ther 197:83\u2013102. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.11.010","journal-title":"Pharmacol Ther"},{"issue":"6","key":"6083_CR70","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"MW Johnson","year":"2008","unstructured":"Johnson MW, Richards WA, Griffiths RR (2008) Human Hallucinogen Research: Guidelines for Safety. Journal of Psychopharmacology (oxford, England) 22(6):603\u2013620. https:\/\/doi.org\/10.1177\/0269881108093587","journal-title":"Journal of Psychopharmacology (oxford, England)"},{"issue":"3","key":"6083_CR71","doi-asserted-by":"publisher","first-page":"411a","DOI":"10.1176\/ajp.149.3.411a","volume":"149","author":"G Kaskey","year":"1992","unstructured":"Kaskey G (1992) Possible interaction between an MAOI and \u201cecstasy.\u201d Am J Psychiatry 149(3):411a\u20134412. https:\/\/doi.org\/10.1176\/ajp.149.3.411a","journal-title":"Am J Psychiatry"},{"key":"6083_CR72","unstructured":"Keeler, M. H. (1967). Chlorpromazine Antagonism of Psilocybin Effect. International Journal of Neuropsychiatry, 3, 66\u201371. https:\/\/bibliography.maps.org\/bibliography\/default\/citation\/1972"},{"key":"6083_CR73","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.genhosppsych.2015.10.007","volume":"39","author":"D Khachatryan","year":"2016","unstructured":"Khachatryan D, Groll D, Booij L, Sepehry AA, Sch\u00fctz CG (2016) Prazosin for treating sleep disturbances in adults with posttraumatic stress disorder: A systematic review and meta-analysis of randomized controlled trials. Gen Hosp Psychiatry 39:46\u201352. https:\/\/doi.org\/10.1016\/j.genhosppsych.2015.10.007","journal-title":"Gen Hosp Psychiatry"},{"issue":"9","key":"6083_CR74","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1097\/00005053-198909000-00005","volume":"177","author":"JD Kinzie","year":"1989","unstructured":"Kinzie JD, Leung P (1989) Clonidine in Cambodian patients with posttraumatic stress disorder. J Nerv Ment Dis 177(9):546\u2013550. https:\/\/doi.org\/10.1097\/00005053-198909000-00005","journal-title":"J Nerv Ment Dis"},{"issue":"6","key":"6083_CR75","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s00213-014-3752-6","volume":"232","author":"MG Kirkpatrick","year":"2015","unstructured":"Kirkpatrick MG, de Wit H (2015) MDMA: A social drug in a social context. Psychopharmacology 232(6):1155\u20131163. https:\/\/doi.org\/10.1007\/s00213-014-3752-6","journal-title":"Psychopharmacology"},{"issue":"3","key":"6083_CR76","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1097\/FTD.0b013e3181684fa0","volume":"30","author":"EA Kolbrich","year":"2008","unstructured":"Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, Huestis MA (2008) Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. Ther Drug Monit 30(3):320\u2013332. https:\/\/doi.org\/10.1097\/FTD.0b013e3181684fa0","journal-title":"Ther Drug Monit"},{"issue":"5","key":"6083_CR77","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1001\/jama.2011.1080","volume":"306","author":"Krystal, J. H., Rosenheck, R. A., Cramer, J. A., Vessicchio, J. C., Jones, K. M., Vertrees, J. E., Horney, R. A., Huang, G. D., Stock, C., & Veterans Affairs Cooperative Study No. 504 Group","year":"2011","unstructured":"Krystal, J. H., Rosenheck, R. A., Cramer, J. A., Vessicchio, J. C., Jones, K. M., Vertrees, J. E., Horney, R. A., Huang, G. D., Stock, C., & Veterans Affairs Cooperative Study No. 504 Group (2011) Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: A randomized trial. JAMA 306(5):493\u2013502. https:\/\/doi.org\/10.1001\/jama.2011.1080","journal-title":"JAMA"},{"issue":"12","key":"6083_CR78","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0006-3223(98)00021-3","volume":"43","author":"H Lauerma","year":"1998","unstructured":"Lauerma H, Wuorela M, Halme M (1998) Interaction of serotonin reuptake inhibitor and 3,4-methylenedioxymethamphetamine? Biol Psychiat 43(12):929","journal-title":"Biol Psychiat"},{"issue":"12","key":"6083_CR79","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1177\/0269881118793086","volume":"32","author":"JB Leonard","year":"2018","unstructured":"Leonard JB, Anderson B, Klein-Schwartz W (2018) Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016. Journal of Psychopharmacology (oxford, England) 32(12):1286\u20131294. https:\/\/doi.org\/10.1177\/0269881118793086","journal-title":"Journal of Psychopharmacology (oxford, England)"},{"issue":"5","key":"6083_CR80","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S0893-133X(99)00148-7","volume":"22","author":"ME Liechti","year":"2000","unstructured":"Liechti ME (2000) Acute Psychological Effects of 3,4-Methylenedioxymethamphetamine (MDMA, \u201cEcstasy\u201d) are Attenuated by the Serotonin Uptake Inhibitor Citalopram. Neuropsychopharmacology 22(5):513\u2013521. https:\/\/doi.org\/10.1016\/S0893-133X(99)00148-7","journal-title":"Neuropsychopharmacology"},{"key":"6083_CR81","doi-asserted-by":"publisher","unstructured":"Liechti, M. E., Geyer, M. A., Hell, D., & Vollenweider, F. X. (2001). Effects of MDMA (ecstasy) on prepulse inhibition and habituation of startle in humans after pretreatment with citalopram, haloperidol, or ketanserin. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 24(3), 240\u2013252. https:\/\/doi.org\/10.1016\/S0893-133X(00)00199-8","DOI":"10.1016\/S0893-133X(00)00199-8"},{"issue":"3","key":"6083_CR82","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/026988110001400313","volume":"14","author":"ME Liechti","year":"2000","unstructured":"Liechti ME, Vollenweider FX (2000a) The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3, 4-methylenedioxymethamphetamine (\u2018Ecstasy\u2019) in healthy volunteers. J Psychopharmacol 14(3):269\u2013274. https:\/\/doi.org\/10.1177\/026988110001400313","journal-title":"J Psychopharmacol"},{"issue":"4","key":"6083_CR83","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S0924-977X(00)00086-9","volume":"10","author":"ME Liechti","year":"2000","unstructured":"Liechti ME, Vollenweider FX (2000b) Acute psychological and physiological effects of MDMA (\u201cEcstasy\u201d) after haloperidol pretreatment in healthy humans. Eur Neuropsychopharmacol 10(4):289\u2013295. https:\/\/doi.org\/10.1016\/S0924-977X(00)00086-9","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"6083_CR84","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3109\/14756366.2010.518965","volume":"26","author":"Y Liu","year":"2011","unstructured":"Liu Y, She M, Wu Z, Dai R (2011) The inhibition study of human UDP-glucuronosyltransferases with cytochrome P450 selective substrates and inhibitors. J Enzyme Inhib Med Chem 26(3):386\u2013393. https:\/\/doi.org\/10.3109\/14756366.2010.518965","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"4","key":"6083_CR85","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/BF00178519","volume":"88","author":"RA Lyon","year":"1986","unstructured":"Lyon RA, Glennon RA, Titeler M (1986) 3,4-Methylenedioxymethamphetamine (MDMA): Stereoselective interactions at brain 5-HT1 and 5-HT2 receptors. Psychopharmacology 88(4):525\u2013526. https:\/\/doi.org\/10.1007\/BF00178519","journal-title":"Psychopharmacology"},{"key":"6083_CR86","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-021-05876-x","author":"B Malcolm","year":"2021","unstructured":"Malcolm B, Thomas K (2021) Serotonin toxicity of serotonergic psychedelics. Psychopharmacology. https:\/\/doi.org\/10.1007\/s00213-021-05876-x","journal-title":"Psychopharmacology"},{"issue":"3","key":"6083_CR87","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1124\/dmd.109.031138","volume":"38","author":"N Manevski","year":"2010","unstructured":"Manevski N, Kurkela M, H\u00f6glund C, Mauriala T, Court MH, Yli-Kauhaluoma J, Finel M (2010) Glucuronidation of psilocin and 4-hydroxyindole by the human UDP-glucuronosyltransferases. Drug Metabolism and Disposition: the Biological Fate of Chemicals 38(3):386\u2013395. https:\/\/doi.org\/10.1124\/dmd.109.031138","journal-title":"Drug Metabolism and Disposition: the Biological Fate of Chemicals"},{"key":"6083_CR88","doi-asserted-by":"publisher","unstructured":"Mattusek, N., & Halbach, A. (1964). \u00dcber den Einfluss von Ergotamin auf die LSD-\"Psychose\" beim Menschen. [On the Influence of Ergotamine on LSD-\"Psychosis\" in Man]. In Psychopharmacologia (Vol. 5, pp. 158\u2013160). https:\/\/doi.org\/10.1007\/BF00413052","DOI":"10.1007\/BF00413052"},{"issue":"3","key":"6083_CR89","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1097\/00004714-199306000-00011","volume":"13","author":"UD McCann","year":"1993","unstructured":"McCann UD, Ricaurte GA (1993) Reinforcing subjective effects of (+\/-) 3,4-methylenedioxymethamphetamine (\u201cecstasy\u201d) may be separable from its neurotoxic actions: Clinical evidence. J Clin Psychopharmacol 13(3):214\u2013217","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"6083_CR90","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","volume":"27","author":"JM Mitchell","year":"2021","unstructured":"Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, G, M. O., Garas, W., Paleos, C., Gorman, I., Nicholas, C., Mithoefer, M., Carlin, S., Poulter, B., Mithoefer, A., Quevedo, S., Wells, G., Klaire, S. S., van der Kolk, B., \u2026 Doblin, R. (2021) MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nat Med 27(6):1025\u20131033. https:\/\/doi.org\/10.1038\/s41591-021-01336-3","journal-title":"Nat Med"},{"issue":"5","key":"6083_CR91","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S2215-0366(15)00576-3","volume":"3","author":"MC Mithoefer","year":"2016","unstructured":"Mithoefer MC, Grob CS, Brewerton TD (2016) Novel psychopharmacological therapies for psychiatric disorders: Psilocybin and MDMA. The Lancet Psychiatry 3(5):481\u2013488. https:\/\/doi.org\/10.1016\/S2215-0366(15)00576-3","journal-title":"The Lancet Psychiatry"},{"issue":"4","key":"6083_CR92","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/0269881110378371","volume":"25","author":"MC Mithoefer","year":"2011","unstructured":"Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R (2011) The safety and efficacy of \u00b13,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: The first randomized controlled pilot study. Journal of Psychopharmacology (oxford, England) 25(4):439\u2013452. https:\/\/doi.org\/10.1177\/0269881110378371","journal-title":"Journal of Psychopharmacology (oxford, England)"},{"issue":"7","key":"6083_CR93","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/j.1360-0443.2011.03399.x","volume":"106","author":"KM Morefield","year":"2011","unstructured":"Morefield KM, Keane M, Felgate P, White JM, Irvine RJ (2011) Pill content, dose and resulting plasma concentrations of 3,4-methylendioxymethamphetamine (MDMA) in recreational \u2018ecstasy\u2019 users. Addiction 106(7):1293\u20131300. https:\/\/doi.org\/10.1111\/j.1360-0443.2011.03399.x","journal-title":"Addiction"},{"issue":"11","key":"6083_CR94","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.4088\/jcp.v67n1110","volume":"67","author":"FA Moreno","year":"2006","unstructured":"Moreno FA, Wiegand CB, Taitano EK, Delgado PL (2006) Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 67(11):1735\u20131740. https:\/\/doi.org\/10.4088\/jcp.v67n1110","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"6083_CR95","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41386-020-00906-2","volume":"46","author":"F M\u00fcller","year":"2021","unstructured":"M\u00fcller F, Holze F, Dolder P, Ley L, Vizeli P, Soltermann A, Liechti ME, Borgwardt S (2021) MDMA-induced changes in within-network connectivity contradict the specificity of these alterations for the effects of serotonergic hallucinogens. Neuropsychopharmacology 46(3):545\u2013553. https:\/\/doi.org\/10.1038\/s41386-020-00906-2","journal-title":"Neuropsychopharmacology"},{"key":"6083_CR96","unstructured":"Multidisciplinary Association for Psychedelic Studies. (2021). MAPS MDMA Investigator\u2019s Brochure."},{"issue":"7754","key":"6083_CR97","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41586-019-1075-9","volume":"569","author":"R Nardou","year":"2019","unstructured":"Nardou R, Lewis EM, Rothhaas R, Xu R, Yang A, Boyden E, D\u00f6len G (2019) Oxytocin-dependent reopening of a social reward learning critical period with MDMA. Nature 569(7754):116\u2013120. https:\/\/doi.org\/10.1038\/s41586-019-1075-9","journal-title":"Nature"},{"key":"6083_CR98","doi-asserted-by":"publisher","unstructured":"Nayak, S., Gukasyan, N., Barrett, F. S., Erowid, E., Erowid, F., & Griffiths, R. R. (2021). Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: An analysis of online psychedelic experience reports. PsyArXiv. https:\/\/doi.org\/10.31234\/osf.io\/r726d","DOI":"10.31234\/osf.io\/r726d"},{"issue":"10","key":"6083_CR99","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41429-020-0311-8","volume":"73","author":"DE Nichols","year":"2020","unstructured":"Nichols DE (2020) Psilocybin: From ancient magic to modern medicine. J Antibiot 73(10):679\u2013686. https:\/\/doi.org\/10.1038\/s41429-020-0311-8","journal-title":"J Antibiot"},{"issue":"5","key":"6083_CR100","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1177\/0269881120920420","volume":"35","author":"HE Oeri","year":"2021","unstructured":"Oeri HE (2021) Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy. J Psychopharmacol 35(5):512\u2013536. https:\/\/doi.org\/10.1177\/0269881120920420","journal-title":"J Psychopharmacol"},{"issue":"5","key":"6083_CR101","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/JCP.0b013e318184ff6e","volume":"28","author":"B O\u2019Math\u00fana","year":"2008","unstructured":"O\u2019Math\u00fana B, Farr\u00e9 M, Rostami-Hodjegan A, Yang J, Cuy\u00e0s E, Torrens M, Pardo R, Abanades S, Maluf S, Tucker GT, Torre R (2008) The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. J Clin Psychopharmacol 28(5):523\u2013529. https:\/\/doi.org\/10.1097\/JCP.0b013e318184ff6e","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"6083_CR102","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1124\/jpet.103.061374","volume":"309","author":"R Pacifici","year":"2004","unstructured":"Pacifici R, Pichini S, Zuccaro P, Farr\u00e9 M, Segura M, Ortu\u00f1o J, Di Carlo S, Bacosi A, Roset PN, Segura J, de la Torre R (2004) Paroxetine Inhibits Acute Effects of 3,4-Methylenedioxymethamphetamine on the Immune System in Humans. J Pharmacol Exp Ther 309(1):285\u2013292. https:\/\/doi.org\/10.1124\/jpet.103.061374","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"6083_CR103","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/17425255.2020.1749262","volume":"16","author":"E Papaseit","year":"2020","unstructured":"Papaseit E, P\u00e9rez-Ma\u00f1\u00e1 C, Torrens M, Farr\u00e9 A, Poyatos L, Hladun O, Sanvisens A, Muga R, Farr\u00e9 M (2020) MDMA interactions with pharmaceuticals and drugs of abuse. Expert Opin Drug Metab Toxicol 16(5):357\u2013369. https:\/\/doi.org\/10.1080\/17425255.2020.1749262","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"7","key":"6083_CR104","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s00134-012-2537-9","volume":"38","author":"E Papaseit","year":"2012","unstructured":"Papaseit E, V\u00e1zquez A, P\u00e9rez-Ma\u00f1\u00e1 C, Pujadas M, de la Torre R, Farr\u00e9 M, Nolla J (2012) Surviving life-threatening MDMA (3,4-methylenedioxymethamphetamine, ecstasy) toxicity caused by ritonavir (RTV). Intensive Care Med 38(7):1239\u20131240. https:\/\/doi.org\/10.1007\/s00134-012-2537-9","journal-title":"Intensive Care Med"},{"issue":"1","key":"6083_CR105","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1124\/jpet.106.103622","volume":"319","author":"JS Partilla","year":"2006","unstructured":"Partilla JS, Dempsey AG, Nagpal AS, Blough BE, Baumann MH, Rothman RB (2006) Interaction of Amphetamines and Related Compounds at the Vesicular Monoamine Transporter. J Pharmacol Exp Ther 319(1):237\u2013246. https:\/\/doi.org\/10.1124\/jpet.106.103622","journal-title":"J Pharmacol Exp Ther"},{"key":"6083_CR106","doi-asserted-by":"publisher","first-page":"205032451876744","DOI":"10.1177\/2050324518767442","volume":"4","author":"T Passie","year":"2018","unstructured":"Passie T (2018) The early use of MDMA (\u2018Ecstasy\u2019) in psychotherapy (1977\u20131985). Drug Science, Policy and Law 4:2050324518767442. https:\/\/doi.org\/10.1177\/2050324518767442","journal-title":"Drug Science, Policy and Law"},{"issue":"7474","key":"6083_CR107","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nature12533","volume":"503","author":"A Penmatsa","year":"2013","unstructured":"Penmatsa A, Wang KH, Gouaux E (2013) X-ray structure of dopamine transporter elucidates antidepressant mechanism. Nature 503(7474):85\u201390. https:\/\/doi.org\/10.1038\/nature12533","journal-title":"Nature"},{"issue":"6","key":"6083_CR108","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nsmb.3029","volume":"22","author":"A Penmatsa","year":"2015","unstructured":"Penmatsa A, Wang KH, Gouaux E (2015) X-ray structures of Drosophila dopamine transporter in complex with nisoxetine and reboxetine. Nat Struct Mol Biol 22(6):506\u2013508. https:\/\/doi.org\/10.1038\/nsmb.3029","journal-title":"Nat Struct Mol Biol"},{"issue":"1\u20133","key":"6083_CR109","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.forsciint.2011.04.008","volume":"215","author":"JL Pilgrim","year":"2012","unstructured":"Pilgrim JL, Gerostamoulos D, Woodford N, Drummer OH (2012) Serotonin toxicity involving MDMA (ecstasy) and moclobemide. Forensic Sci Int 215(1\u20133):184\u2013188. https:\/\/doi.org\/10.1016\/j.forsciint.2011.04.008","journal-title":"Forensic Sci Int"},{"issue":"4","key":"6083_CR110","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.euroneuro.2016.01.005","volume":"26","author":"T Pokorny","year":"2016","unstructured":"Pokorny T, Preller KH, Kraehenmann R, Vollenweider FX (2016) Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A\/2A agonist ergotamine on psilocybin-induced psychedelic experience. Eur Neuropsychopharmacol 26(4):756\u2013766. https:\/\/doi.org\/10.1016\/j.euroneuro.2016.01.005","journal-title":"Eur Neuropsychopharmacol"},{"issue":"7","key":"6083_CR111","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3109\/15563659809162623","volume":"36","author":"S Ramcharan","year":"1998","unstructured":"Ramcharan S, Meenhorst P, Otten J, Koks C, de Boer D, Maes R, Beijnen J (1998) Survival After Massive Ecstasy Overdose. J Toxicol Clin Toxicol 36(7):727\u2013731. https:\/\/doi.org\/10.3109\/15563659809162623","journal-title":"J Toxicol Clin Toxicol"},{"issue":"3","key":"6083_CR112","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1177\/1074248416681644","volume":"22","author":"JR Richards","year":"2017","unstructured":"Richards JR, Hollander JE, Ramoska EA, Fareed FN, Sand IC, G\u00f3mez MMI, Lange RA (2017) \u03b2-Blockers, Cocaine, and the Unopposed \u03b1-Stimulation Phenomenon. J Cardiovasc Pharmacol Ther 22(3):239\u2013249. https:\/\/doi.org\/10.1177\/1074248416681644","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"8","key":"6083_CR113","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.euroneuro.2016.05.001","volume":"26","author":"A Rickli","year":"2016","unstructured":"Rickli A, Moning OD, Hoener MC, Liechti ME (2016) Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol 26(8):1327\u20131337. https:\/\/doi.org\/10.1016\/j.euroneuro.2016.05.001","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"6083_CR114","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1080\/14659891.2018.1436607","volume":"23","author":"KK Rigg","year":"2018","unstructured":"Rigg KK, Sharp A (2018) Deaths related to MDMA (ecstasy\/molly): Prevalence, root causes, and harm reduction interventions. Journal of Substance Use 23(4):345\u2013352. https:\/\/doi.org\/10.1080\/14659891.2018.1436607","journal-title":"Journal of Substance Use"},{"key":"6083_CR115","doi-asserted-by":"publisher","unstructured":"Roseman L, Leech R, Feilding A, Nutt DJ, Carhart-Harris RL (2014) The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers. Front Hum Neurosci 8. https:\/\/doi.org\/10.3389\/fnhum.2014.00204","DOI":"10.3389\/fnhum.2014.00204"},{"issue":"5","key":"6083_CR116","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1073\/pnas.89.5.1817","volume":"89","author":"G Rudnick","year":"1992","unstructured":"Rudnick G, Wall SC (1992) The molecular mechanism of \u201cecstasy\u201d [3,4-methylenedioxy-methamphetamine (MDMA)]: Serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci 89(5):1817\u20131821. https:\/\/doi.org\/10.1073\/pnas.89.5.1817","journal-title":"Proc Natl Acad Sci"},{"issue":"8","key":"6083_CR117","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1177\/0269881117715596","volume":"31","author":"S Saleemi","year":"2017","unstructured":"Saleemi S, Pennybaker SJ, Wooldridge M, Johnson MW (2017) Who is \u201cMolly\u201d? MDMA adulterants by product name and the impact of harm-reduction services at raves. Journal of Psychopharmacology (oxford, England) 31(8):1056\u20131060. https:\/\/doi.org\/10.1177\/0269881117715596","journal-title":"Journal of Psychopharmacology (oxford, England)"},{"key":"6083_CR118","doi-asserted-by":"crossref","unstructured":"Schatzberg, A. F., & Nemeroff, C. B. (2017). The American Psychiatric Association Publishing Textbook Of Psychopharmacology. American Psychiatric Pub.","DOI":"10.1176\/appi.books.9781615371624"},{"key":"6083_CR119","doi-asserted-by":"publisher","unstructured":"Scherrer, J. F., Salas, J., Cohen, B. E., Schnurr, P. P., Schneider, F. D., Chard, K. M., Tuerk, P., Friedman, M. J., Norman, S. B., van den Berk\u2010Clark, C., & Lustman, P. J. (2019). Comorbid Conditions Explain the Association Between Posttraumatic Stress Disorder and Incident Cardiovascular Disease. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 8(4). https:\/\/doi.org\/10.1161\/JAHA.118.011133","DOI":"10.1161\/JAHA.118.011133"},{"issue":"1","key":"6083_CR120","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1124\/jpet.114.222356","volume":"353","author":"Y Schmid","year":"2015","unstructured":"Schmid Y, Rickli A, Schaffner A, Duthaler U, Grouzmann E, Hysek CM, Liechti ME (2015) Interactions between Bupropion and 3,4-Methylenedioxymethamphetamine in Healthy Subjects. J Pharmacol Exp Ther 353(1):102\u2013111. https:\/\/doi.org\/10.1124\/jpet.114.222356","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"6083_CR121","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/FPC.0000000000000231","volume":"26","author":"Y Schmid","year":"2016","unstructured":"Schmid Y, Vizeli P, Hysek CM, Prestin K, Meyer zu Schwabedissen, H. E., & Liechti, M. E. (2016) CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals. Pharmacogenet Genomics 26(8):397\u2013401. https:\/\/doi.org\/10.1097\/FPC.0000000000000231","journal-title":"Pharmacogenet Genomics"},{"key":"6083_CR122","doi-asserted-by":"publisher","unstructured":"Scriba, G. K. E. (2011). Sean C. Sweetman (Ed.): Martindale: The Complete Drug Reference. Chromatographia, 74(7), 647\u2013648. https:\/\/doi.org\/10.1007\/s10337-011-2101-8","DOI":"10.1007\/s10337-011-2101-8"},{"issue":"6","key":"6083_CR123","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2165\/00003088-200544060-00006","volume":"44","author":"M Segura","year":"2005","unstructured":"Segura M, Farre M, Pichini S, Peiro AM, Roset PN, Ramirez A, Ortuno J, Pacifici R, Zuccaro P, Segura J, de la Torre R (2005) Contribution of Cytochrome P450 2D6 to 3,4-Methylenedioxymethamphetamine Disposition in Humans: Use of Paroxetine as a Metabolic Inhibitor Probe. Clin Pharmacokinet 44(6):649\u2013660. https:\/\/doi.org\/10.2165\/00003088-200544060-00006","journal-title":"Clin Pharmacokinet"},{"key":"6083_CR124","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.neulet.2016.07.004","volume":"649","author":"B Sessa","year":"2017","unstructured":"Sessa B (2017) MDMA and PTSD treatment: \u201cPTSD: From novel pathophysiology to innovative therapeutics.\u201d Neurosci Lett 649:176\u2013180. https:\/\/doi.org\/10.1016\/j.neulet.2016.07.004","journal-title":"Neurosci Lett"},{"issue":"4","key":"6083_CR125","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1177\/0269881121991792","volume":"35","author":"B Sessa","year":"2021","unstructured":"Sessa B, Higbed L, O\u2019Brien S, Durant C, Sakal C, Titheradge D, Williams TM, Rose-Morris A, Brew-Girard E, Burrows S, Wiseman C, Wilson S, Rickard J, Nutt DJ (2021) First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder. J Psychopharmacol 35(4):375\u2013383. https:\/\/doi.org\/10.1177\/0269881121991792","journal-title":"J Psychopharmacol"},{"issue":"4","key":"6083_CR126","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/02791072.1986.10472361","volume":"18","author":"AT Shulgin","year":"1986","unstructured":"Shulgin AT (1986) The background and chemistry of MDMA. J Psychoactive Drugs 18(4):291\u2013304. https:\/\/doi.org\/10.1080\/02791072.1986.10472361","journal-title":"J Psychoactive Drugs"},{"issue":"8","key":"6083_CR127","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1080\/00048670701449237","volume":"41","author":"E Silins","year":"2007","unstructured":"Silins E, Copeland J, Dillon P (2007) Qualitative Review of Serotonin Syndrome, Ecstasy (MDMA) and the use of Other Serotonergic Substances: Hierarchy of Risk. Aust N Z J Psychiatry 41(8):649\u2013655. https:\/\/doi.org\/10.1080\/00048670701449237","journal-title":"Aust N Z J Psychiatry"},{"issue":"9","key":"6083_CR128","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1210\/jc.2011-1143","volume":"96","author":"LD Simmler","year":"2011","unstructured":"Simmler LD, Hysek CM, Liechti ME (2011) Sex Differences in the Effects of MDMA (Ecstasy) on Plasma Copeptin in Healthy Subjects. J Clin Endocrinol Metab 96(9):2844\u20132850. https:\/\/doi.org\/10.1210\/jc.2011-1143","journal-title":"J Clin Endocrinol Metab"},{"issue":"1\u20132","key":"6083_CR129","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3109\/15563658708992620","volume":"25","author":"MJ Smilkstein","year":"1987","unstructured":"Smilkstein MJ, Smolinske SC, Rumack BH (1987) A Case of Mao Inhibitor\/MDMA Interaction: Agony After Ecstasy. J Toxicol Clin Toxicol 25(1\u20132):149\u2013159. https:\/\/doi.org\/10.3109\/15563658708992620","journal-title":"J Toxicol Clin Toxicol"},{"key":"6083_CR130","doi-asserted-by":"crossref","unstructured":"Stein, D. J., & Rink, J. (1999). Effects of \u201cEcstasy\u201d Blocked by Serotonin Reuptake Inhibitors. The Journal of Clinical Psychiatry, 60(7), 485\u2013485. https:\/\/www.psychiatrist.com\/JCP\/article\/Pages\/effects-ecstasy-blocked-serotonin-reuptake-inhibitors.aspx","DOI":"10.4088\/JCP.v60n0711a"},{"issue":"3","key":"6083_CR131","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150955","volume":"11","author":"AE Steuer","year":"2016","unstructured":"Steuer AE, Schmidhauser C, Tingelhoff EH, Schmid Y, Rickli A, Kraemer T, Liechti ME (2016) Impact of Cytochrome P450 2D6 Function on the Chiral Blood Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine (MDMA) and Its Phase I and II Metabolites in Humans. PLoS ONE 11(3):e0150955. https:\/\/doi.org\/10.1371\/journal.pone.0150955","journal-title":"PLoS ONE"},{"key":"6083_CR132","unstructured":"Strassman, R. (1992). Human Hallucinogen Interactions with Drugs Affecting Serotonergic. Neuropsychopharmacol, 7(3)."},{"key":"6083_CR133","doi-asserted-by":"publisher","unstructured":"Studerus, E., Gamma, A., & Vollenweider, F. X. (2010). Psychometric Evaluation of the Altered States of Consciousness Rating Scale (OAV). PLoS ONE, 5(8). https:\/\/doi.org\/10.1371\/journal.pone.0012412","DOI":"10.1371\/journal.pone.0012412"},{"key":"6083_CR134","doi-asserted-by":"publisher","unstructured":"Studerus E, Vizeli P, Harder S, Ley L, Liechti ME (2021) Prediction of MDMA response in healthy humans: A pooled analysis of placebo-controlled studies. J Psychopharmacol 0269881121998322. https:\/\/doi.org\/10.1177\/0269881121998322","DOI":"10.1177\/0269881121998322"},{"issue":"4","key":"6083_CR135","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00213-006-0576-z","volume":"189","author":"M Tancer","year":"2006","unstructured":"Tancer M, Johanson C-E (2006) The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 189(4):565\u2013573. https:\/\/doi.org\/10.1007\/s00213-006-0576-z","journal-title":"Psychopharmacology"},{"issue":"5","key":"6083_CR136","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1080\/02791072.2017.1320734","volume":"49","author":"K Thomas","year":"2017","unstructured":"Thomas K, Malcolm B, Lastra D (2017) Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders. J Psychoactive Drugs 49(5):446\u2013455. https:\/\/doi.org\/10.1080\/02791072.2017.1320734","journal-title":"J Psychoactive Drugs"},{"issue":"1","key":"6083_CR137","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/1556-4029.12584","volume":"60","author":"LR Togni","year":"2015","unstructured":"Togni LR, Lanaro R, Resende RR, Costa JL (2015) The variability of ecstasy tablets composition in Brazil. J Forensic Sci 60(1):147\u2013151. https:\/\/doi.org\/10.1111\/1556-4029.12584","journal-title":"J Forensic Sci"},{"key":"6083_CR138","unstructured":"Usona Institute. (2021). Usona Institute Psilocybin Investigator\u2019s Brochure (Vol. 4)."},{"key":"6083_CR139","unstructured":"VA\/DOD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder. (2017) 200"},{"issue":"4","key":"6083_CR140","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/hup.2431","volume":"30","author":"G Valeriani","year":"2015","unstructured":"Valeriani G, Corazza O, Bersani FS, Melcore C, Metastasio A, Bersani G, Schifano F (2015) Olanzapine as the ideal \u201ctrip terminator\u201d? Analysis of online reports relating to antipsychotics\u2019 use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms. Hum Psychopharmacol 30(4):249\u2013254. https:\/\/doi.org\/10.1002\/hup.2431","journal-title":"Hum Psychopharmacol"},{"issue":"9","key":"6083_CR141","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3390\/biomedicines8090331","volume":"8","author":"AS Vargas","year":"2020","unstructured":"Vargas AS, Lu\u00eds \u00c2, Barroso M, Gallardo E, Pereira L (2020) Psilocybin as a New Approach to Treat Depression and Anxiety in the Context of Life-Threatening Diseases\u2014A Systematic Review and Meta-Analysis of Clinical Trials. Biomedicines 8(9):331. https:\/\/doi.org\/10.3390\/biomedicines8090331","journal-title":"Biomedicines"},{"issue":"4","key":"6083_CR142","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00213-005-0174-5","volume":"189","author":"CD Verrico","year":"2007","unstructured":"Verrico CD, Miller GM, Madras BK (2007) MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: Implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology 189(4):489\u2013503. https:\/\/doi.org\/10.1007\/s00213-005-0174-5","journal-title":"Psychopharmacology"},{"issue":"3","key":"6083_CR143","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.euroneuro.2017.01.008","volume":"27","author":"P Vizeli","year":"2017","unstructured":"Vizeli P, Schmid Y, Prestin K, Schwabedissen MZ, H. E., & Liechti, M. E. (2017) Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects. European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology 27(3):232\u2013238. https:\/\/doi.org\/10.1016\/j.euroneuro.2017.01.008","journal-title":"European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology"},{"key":"6083_CR144","doi-asserted-by":"publisher","unstructured":"Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., B\u00e4bler, A., Vogel, H., & Hell, D. (1998). Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action: NeuroReport, 9(17), 3897\u20133902. https:\/\/doi.org\/10.1097\/00001756-199812010-00024","DOI":"10.1097\/00001756-199812010-00024"},{"issue":"3","key":"6083_CR145","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1046\/j.1360-0443.2003.00292.x","volume":"98","author":"E Vuori","year":"2003","unstructured":"Vuori E, Henry JA, Ojanper\u00e4 I, Nieminen R, Savolainen T, Wahlsten P, J\u00e4ntti M (2003) Death following ingestion of MDMA (ecstasy) and moclobemide: Fatal MDMA-moclobemide interaction. Addiction 98(3):365\u2013368. https:\/\/doi.org\/10.1046\/j.1360-0443.2003.00292.x","journal-title":"Addiction"},{"issue":"8","key":"6083_CR146","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1177\/0269881117711712","volume":"31","author":"MT Wagner","year":"2017","unstructured":"Wagner MT, Mithoefer MC, Mithoefer AT, MacAulay RK, Jerome L, Yazar-Klosinski B, Doblin R (2017) Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy. Journal of Psychopharmacology (oxford, England) 31(8):967\u2013974. https:\/\/doi.org\/10.1177\/0269881117711712","journal-title":"Journal of Psychopharmacology (oxford, England)"},{"issue":"4","key":"6083_CR147","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/s0091-3057(02)00818-3","volume":"73","author":"TL White","year":"2002","unstructured":"White TL, Justice AJH, de Wit H (2002) Differential subjective effects of D-amphetamine by gender, hormone levels and menstrual cycle phase. Pharmacol Biochem Behav 73(4):729\u2013741. https:\/\/doi.org\/10.1016\/s0091-3057(02)00818-3","journal-title":"Pharmacol Biochem Behav"},{"issue":"9","key":"6083_CR148","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1136\/emj.2010.092270","volume":"28","author":"DM Wood","year":"2011","unstructured":"Wood DM, Stribley V, Dargan PI, Davies S, Holt DW, Ramsey J (2011) Variability in the 3,4-methylenedioxymethamphetamine content of \u201cecstasy\u201d tablets in the UK. Emergency Medicine Journal: EMJ 28(9):764\u2013765. https:\/\/doi.org\/10.1136\/emj.2010.092270","journal-title":"Emergency Medicine Journal: EMJ"},{"issue":"1","key":"6083_CR149","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1556\/2054.2020.00159","volume":"5","author":"A Yockey","year":"2021","unstructured":"Yockey A, King K (2021) Use of psilocybin (\u201cmushrooms\u201d) among US adults: 2015\u20132018. Journal of Psychedelic Studies 5(1):17\u201321. https:\/\/doi.org\/10.1556\/2054.2020.00159","journal-title":"Journal of Psychedelic Studies"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-022-06083-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-022-06083-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-022-06083-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T02:08:41Z","timestamp":1654222121000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-022-06083-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,7]]},"references-count":149,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["6083"],"URL":"https:\/\/doi.org\/10.1007\/s00213-022-06083-y","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,7]]},"assertion":[{"value":"4 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CSS has received payment from the MAPS Public Benefit Corporation for Training clinicians in MAP. BM runs\n                      \n                      , which offers a monthly membership service for access to drug interactions guides, courses, and consultation services. AS and KT have no conflicts of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}